Take­da en­lists Po­sei­da in $3.6B+ non­vi­ral gene ther­a­py deal, though da­ta re­main years away from hu­man stud­ies

Take­da has been be­hind oth­er ma­jor play­ers in terms of cell and gene ther­a­py de­vel­op­ment, but af­ter an­nounc­ing a col­lab­o­ra­tion with Se­lec­ta Bio­sciences last week, it’s now on a bit of a spend­ing spree.

The Big Phar­ma has re­cruit­ed Po­sei­da Ther­a­peu­tics to de­vel­op in vi­vo gene ther­a­pies in six dif­fer­ent in­di­ca­tions, the com­pa­nies an­nounced Tues­day, with Take­da re­tain­ing an op­tion to ask for two more. Po­sei­da will get a $45 mil­lion up­front pay­ment in the deal, $125 mil­lion in short-term pre­clin­i­cal mile­stones and up to $435 mil­lion in clin­i­cal mile­stones per pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER